Allmed Solutions Ltd (ALMD) Fair Value & Analysis
Healthcare · Il · Market cap 32.6M ILA
Fair value as of: Jul 14, 2026
From 2 valuation models · updated today
Fair value updated Jul 14, 2026 — revised from 1.18 ILA to 0.1300 ILA (−89.0%) since Jun 24, 2026. Share price +5.9% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.2890 ILA – 0.3970 ILA · fair‑value band 0.1000 ILA – 0.1800 ILA · the 0.3390 ILA price screens above the 0.1300 ILA fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Allmed Solutions Ltd (ALMD) currently trades at 0.3390 ILA, while our model-based Fair Value estimate is 0.1300 ILA — implying the stock looks roughly 61.7% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 283K ILA. It earns a return on equity of -40.3%. The balance sheet holds a net cash position of 3.3M ILA. Fundamentals as of Jul 14, 2026
Our scenario range runs from 0.1000 ILA (bear case) to 0.1800 ILA (bull case); at 0.3390 ILA, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -29% fair-value upside — at -62%, ALMD screens richer than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Allmed Solutions Ltd develops, manufactures, and markets minimally invasive products in various medical disciplines in Israel and internationally. The company offers drugs, biological products, and medical devices; and ProCatid system, a distal embolic protection system comprised of an independent filter unit that can be delivered, locked, and deployed on any commercially marketed guide wires. It is also involved in the development of a mitral valve regurgitation solution. The company was formerly known as Allium Medical Solutions Ltd. Allmed Solutions Ltd was incorporated in 2004 and is based in Or Akiva, Israel.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Allmed Solutions Ltd reported revenue of 0 ILA in FY2025 versus 5.5M ILA in FY2021. Reported net income was −14.1K ILA in FY2025.
Is ALMD fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABL | €78.04 | €61.19 | -22% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| DexCom, Inc DXCM | $68.92 | $38.95 | -43% |
| GE HealthCare Technologies Inc GEHC | $63.76 | $44.97 | -29% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Allmed Solutions Ltd (ALMD) undervalued?
What is the fair value of ALMD?
What is the quality score of ALMD?
What is the revenue of Allmed Solutions Ltd (ALMD)?
What is the net profit margin of ALMD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Allmed Solutions Ltd analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.